Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Trellus Health PLC ( (GB:TRLS) ) has issued an announcement.
Trellus Health plc has issued 5,637,205 new ordinary shares following the conversion of £21,000 of principal under its secured convertible loan notes, in line with shareholder approvals granted in January. The new shares are expected to be admitted to trading on AIM around 19 February 2026, modestly diluting existing holders but strengthening the company’s equity base.
Following admission, Trellus Health will have 191,914,768 ordinary shares in issue and no shares held in treasury, establishing this figure as the new denominator for calculating voting rights disclosures. The updated capital structure provides investors and regulators with a clear reference point for monitoring ownership changes under the FCA’s disclosure and transparency rules.
The most recent analyst rating on (GB:TRLS) stock is a Hold with a £0.74 price target. To see the full list of analyst forecasts on Trellus Health PLC stock, see the GB:TRLS Stock Forecast page.
Spark’s Take on GB:TRLS Stock
According to Spark, TipRanks’ AI Analyst, GB:TRLS is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, negative free cash flow, and declining equity—despite the benefit of having no debt. Technicals are the main positive, with strong momentum above major moving averages, but valuation remains constrained by loss-making results and no indicated dividend yield.
To see Spark’s full report on GB:TRLS stock, click here.
More about Trellus Health PLC
Trellus Health plc is a healthcare company that delivers Trellus Elevate, a digital, resilience-based platform integrating data analytics, personalised self-management programs, and expert coaching to manage complex chronic conditions. The company initially targets high-cost gastrointestinal diseases such as inflammatory bowel disease, claiming significant reductions in hospitalisations and emergency room visits, and also partners with pharmaceutical firms from clinical trials through commercialisation.
Average Trading Volume: 2,742,561
Technical Sentiment Signal: Sell
Current Market Cap: £1.02M
For an in-depth examination of TRLS stock, go to TipRanks’ Overview page.